checkAd

     120  0 Kommentare ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - Seite 4

    CONTACTS 

    ERYTECH                            
    Eric Soyer
    CFO & COO     		LifeSci Advisors, LLC
    Investor Relations
    Corey Davis, Ph.D.

          		NewCap
    Mathilde Bohin /
    Louis-Victor Delouvrier
    Investor relations
    Nicolas Merigeau
    Media relations
     

    +33 4 78 74 44 38
    investors@erytech.com

          		 

    +1 (212) 915 - 2577
    cdavis@lifesciadvisors.com     		 

    +33 1 44 71 94 94
    erytech@newcap.eu



    Lesen Sie auch

    Attachment


    Seite 4 von 4




    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer - Seite 4 ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer Trial to evaluate safety of eryaspase in combination with FOLFIRINOX for the first-line treatment of pancreatic …